

HOPE BTK Registry

Treatment of BTK lesions in high-risk patients suffering from Chronic Limb Threatening Ischemia

318
Patients

Patients treated with Sirolimus Coated Balloon

Patients treated with Plain Old Balloon Angioplasty

133

MagicTouch PTA

POBA

185

COMPLEX CLTI COHORT

Diabetes

91% vs 89%

ASA Score (3)

78% vs 76%

WIFI Score

4.1 ± 1.8 vs 3.9 ± 1.9

ESRD


23% vs 22%

PRINCIPAL INVESTIGATOR : PROF. EDWARD CHOKE

3 Year Clinical Outcomes*


Freedom from TLR

MT PTA **76.5%**
POBA **64.9%**




Freedom from Major Amputation

MT PTA **92.8%**
POBA **85.7%**




Amputation Free Survival

MT PTA **60.9%**
POBA **47.4%**



Overall Survival

MT PTA **62.4%**
POBA **53.9%**



Key Takeaways

MagicTouch PTA, compared to POBA, was associated with lower BTK re-intervention, better AFS and survival rate. Long term sustained efficacy and safety upto 3 years indicate the superiority of MagicTouch PTA versus POBA in BTK.

*Presented by Prof. Edward Choke at Charing Cross 2025

